Compare SCHL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | ABUS |
|---|---|---|
| Founded | 1920 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.4M | 848.8M |
| IPO Year | 1995 | 2008 |
| Metric | SCHL | ABUS |
|---|---|---|
| Price | $40.25 | $4.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $5.00 |
| AVG Volume (30 Days) | 262.4K | ★ 1.2M |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ 1.87 | 0.87 |
| Revenue | ★ $1,487,100,000.00 | $14,083,000.00 |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $4.05 | $239.71 |
| P/E Ratio | $21.91 | ★ $5.28 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $16.81 | $3.04 |
| 52 Week High | $43.39 | $5.10 |
| Indicator | SCHL | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 57.10 |
| Support Level | $37.84 | $4.16 |
| Resistance Level | $43.39 | $4.60 |
| Average True Range (ATR) | 1.23 | 0.18 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 68.36 | 67.81 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.